The phagocytic capacity and immunological potency of human dendritic cells is improved by 2,6-sialic acid deficiency

Dendritic cells (DCs) play an essential role in immunity against bacteria by phagocytosis and by eliciting adaptive immune responses. Previously, we demonstrated that human monocyte-derived DCs (MDDCs) express a high content of cell surface 2,6-sialylated glycans. However, the relative role of these sialylated structures in phagocytosis of bacteria has not been reported. Here, we show that treatment with a sialidase significantly improved the capacity of both immature and mature MDDCs to phagocytose Escherichia coli. Desialylated MDDCs had a significantly more mature phenotype, with higher expression of MHC molecules and interleukin (IL)-12, tumour necrosis factor-, IL-6 and IL-10 cytokines, and nuclear factor-B activation. T lymphocytes primed by desialylated MDDCs expressed more interferon- when compared with priming by sialylated MDDCs. Improved phagocytosis required E.coli sialic acids, indicating a mechanism of hostpathogen interaction dependent on sialic acid moieties. The DCs harvested from mice deficient in the ST6Gal.1 sialyltransferase showed improved phagocytosis capacity, demonstrating that the observed sialidase effect was a result of the removal of 2,6-sialic acid. The phagocytosis of different pathogenic E.coli isolates was also enhanced by sialidase, which suggests that modifications on MDDC sialic acids may be considered in the development of MDDC-based antibacterial therapies. Physiologically, our findings shed new light on mechanisms that modulate the function of both immature and mature MDDCs, in the context of hostbacteria interaction. Hence, with particular relevance to DC-based therapies, the engineering of 2,6-sialic acid cell surface is a novel possibility to fine tune DC phagocytosis and immunological potency.